Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
| ▸ | TDO2 | P48775 | 1/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4660911 | 0.86 | POLB (0.42) | PTGS1PTGS2ALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL411771 | 0.83 | PTGS1 (0.49) | PTGS1PTGS2ALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL412173 | 0.81 | PTGS1 (0.52) | PTGS1PTGS2ALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL4660606 | 0.80 | ALDH1A1 (0.37) | ALDH1A1SMN1; SMN2LMNACYP19A1 | |
| SCHEMBL14619400 | 0.80 | PTGS1 (0.46) | PTGS1PTGS2ALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL406868 | 0.80 | PTGS1 (0.57) | PTGS1PTGS2ALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL414011 | 0.78 | ALDH1A1 (0.45) | ALDH1A1SMN1; SMN2LMNAKDM4EHPGD | |
| SCHEMBL411865 | 0.78 | PTGS1 (0.56) | PTGS1PTGS2ALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL10189541 | 0.77 | PTGS1 (0.51) | PTGS1PTGS2ALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL14619072 | 0.76 | PTGS1 (0.48) | PTGS1PTGS2ALDH1A1SMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9175022-B2 | Compounds for the treatment of proliferative disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2015-11-03 | — | — | US | disclosed |
| US-9175022-B2 | Compounds for the treatment of proliferative disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2015-11-03 | — | — | US | disclosed |
| US-20130338112-A1 | COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | SYNTA PHARMACEUTICALS CORP (US) | 2013-12-19 | — | — | US | disclosed |
| US-8501790-B2 | Compounds for the treatment of proliferative disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2013-08-06 | — | — | US | disclosed |
| US-8501790-B2 | Compounds for the treatment of proliferative disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2013-08-06 | — | — | US | disclosed |
| EP-1919881-B1 | 1, 2, 3 -TRIAZOLES INHIBITORS OF TUBULIN POLYMERIZATION FOR THE TREATMENT OF POLIFERATIVE DISORDERS | SYNTA PHARMACEUTICALS CORP (US) | 2013-04-10 | — | — | EP | disclosed |
| US-20120022118-A1 | COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | SYNTA PHARMACEUTICALS CORP. | 2012-01-26 | — | — | US | disclosed |
| US-20120022118-A1 | COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | SYNTA PHARMACEUTICALS CORP. | 2012-01-26 | — | — | US | disclosed |
| US-20100279410-A1 | COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | SYNTA PHARMACEUTICALS CORP. | 2010-11-04 | — | — | US | disclosed |
| US-20100279410-A1 | COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | SYNTA PHARMACEUTICALS CORP. | 2010-11-04 | — | — | US | disclosed |
| US-7781462-B2 | Compounds for the treatment of proliferative disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2010-08-24 | — | — | US | disclosed |
| US-7781462-B2 | Compounds for the treatment of proliferative disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2010-08-24 | — | — | US | disclosed |
| US-20100093670-A1 | Compounds for the treatment of angiogenesis | SYNTA PHARMACEUTICALS CORP. | 2010-04-15 | — | — | US | disclosed |
| EP-2059250-A2 | COMPOUNDS FOR THE TREATMENT OF ANGIOGENESIS | Synta Pharmaceuticals Corporation (US) | 2009-05-20 | — | — | EP | disclosed |
| EP-1919881-A1 | 1, 2, 3 -TRIAZOLES INHIBITORS OF TUBULIN POLYMERIZATION FOR THE TREATMENT OF POLIFERATIVE DISORDERS | Synta Pharmaceuticals Corporation (US) | 2008-05-14 | — | — | EP | disclosed |
| WO-2008033449-A2 | COMPOUNDS FOR THE TREATMENT OF ANGIOGENESIS | SYNTA PHARMACEUTICALS CORP. (US) | 2008-03-20 | — | — | WO | disclosed |
| US-20070238699-A1 | Compounds for the treatment of proliferative disorders | SYNTA PHARMACEUTICALS CORP. | 2007-10-11 | — | — | US | disclosed |
| US-20070238699-A1 | Compounds for the treatment of proliferative disorders | SYNTA PHARMACEUTICALS CORP. | 2007-10-11 | — | — | US | disclosed |
| US-20070238699-A1 | Compounds for the treatment of proliferative disorders | SYNTA PHARMACEUTICALS CORP. | 2007-10-11 | — | — | US | disclosed |
| WO-2007014198-A1 | 1, 2, 3 -TRIAZOLES INHIBITORS OF TUBULIN POLYMERIZATION FOR THE TREATMENT OF POLIFERATIVE DISORDERS | SYNTA PHARMACEUTICALS CORP. (US) | 2007-02-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070238699-A1 | Compounds for the treatment of proliferative disorders | RB1, MKI67, MAPRE1 | PTGS1 2500/4885PTGS2 3488/4885ALDH1A1 1872/4885 |
| US-20120022118-A1 | COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | RB1, MKI67, MAPRE1 | PTGS1 2500/4885PTGS2 3488/4885ALDH1A1 1872/4885 |
| US-20100093670-A1 | Compounds for the treatment of angiogenesis | FLT4, FLT1, TEK | PTGS1 36/4885PTGS2 50/4885ALDH1A1 414/4885 |
| US-20130338112-A1 | COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | RB1, MKI67, MAPRE1 | PTGS1 2500/4885PTGS2 3488/4885ALDH1A1 1872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.